by Dr. Stephen Pelsue
Mon, Jun 29th, 2026 12:56 pm
A surprising story has emerged from the Washington University School of Medicine in St. Louis that challenges conventional thinking in therapeutic development. A group there has engineered a hookworm (Ancylostoma ceylanicum) to be able to deliver a biologic therapeutic. Let that sink in for just a moment. While this is still in the experimental stage, why would infecting someone with a parasite even be considered as a therapeutic approach for disease treatment?
The science behind this is rather fascinating. It involved a clever combination of genetic manipulation and gene editing to introduce a biologic therapeutic—in this case, an anti-toxin antibody—into the hookworm genome, while maintaining genetic stability and enabling secretion of the antibody into the bloodstream. After the hookworm was engineered, eggs from the parasite were used to infect a hamster and the hookworm was allowed to take up residence in the small intestine. They demonstrated that the secreted antibody entered the blood stream and using plasma collected form the hamster, the antibody could neutralize the toxin in an in vitro test. This proof-of-concept study demonstrated that the hookworm can be genetically engineered and can successfully deliver the biologic therapeutic into the bloodstream.
Biologic therapies often require repeated injections or infusions and come with significant cost and treatment burden. What if the therapeutic could be continuously generated, eliminating the need for follow-up treatments? This is a striking example of unconventional, forward-thinking science. While the concept may be surprising at first, it directly targets a major challenge in medicine and represents a remarkably inventive approach to solving it. It is still too early to determine whether this approach will be effective in humans, and the use of hookworm infection raises important concerns, but it remains a fascinating and innovative strategy.